MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: We interpreted these data as indicating that the combination of SFK, MEK, and NF‐κB inhibitors limits the survival of primary CML cells displaying Bcr‐Abl1‐independent mechanisms of survival.